Advaxis

Scientist II

US-Princeton
3 weeks ago
ID
2017-1111
# of Openings
1
Category
Biotech/Pharmaceuticals

Overview

Candidate will be responsible for the for execution, interpretation, and trouble-shooting of molecular biology and microbiology-based laboratory work and experiments in support of advancing our Listeria based immunotherapies.  Candidate should be prepared to follow established protocols, identify and incorporate improved methods, analyze data, and keep meticulous notes.   

 

Responsibilities

  • Perform molecular biology and microbiology-based experiments, and routine laboratory work to support the advancement of our Listeria based immunotherapies. Maintain proper research records as well as data entry/compilation.
  • Reagent preparation, identifying and ordering proper supplies.

Qualifications

EXPERIENCE: 

  • 5+ years experience in a molecular biology or microbiology laboratory setting
  • Expertise with molecular biology laboratory, gene editing, and cloning techniques
  • Experience executing established protocols and applying fundamental knowledge of molecular and micro-biology principles for troubleshooting
  • Ability to work independently as well as coordinate effectively within a team environment
  • Competency with routine laboratory techniques and principles, including biosafety requirements, PCR, gel electrophoresis, autoclave operation etc.
  • Experience working with bacterial culture, DNA and proteins
  • Working knowledge of common computational tools for routine molecular biology data analysis and manipulation, including DNA/protein sequence analysis and alignment, vector design, and primer design

EDUCATION:

  • Minimum BS in molecular biology or related field. Preferred MS in molecular biology or related field.

WORKING CONDITIONS:

  • Flexible work schedule to coordinate with ongoing projects and current company needs, including occasional evening and weekend hours

Options

Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
Share on your newsfeed